The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

This study compared the health and economic benefits of saxagliptin versus insulin as second-line therapy with either metformin (MET) or sulfonylurea (SU) after failure of the respective monotherapies for patients with type 2 diabetes in Poland. The cost-effectiveness was assessed using a previously...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes technology & therapeutics 2012-01, Vol.14 (1), p.65-73
Hauptverfasser:	Grzeszczak, Wladyslaw, Czupryniak, Leszek, Kolasa, Katarzyna, Sciborski, Cezary, Lomon, Isabelle Duprat, McEwan, Phil
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - analogs & derivatives Adamantane - economics Adamantane - therapeutic use Cost-Benefit Analysis Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - economics Diabetes Mellitus, Type 2 - epidemiology Dipeptides - economics Dipeptides - therapeutic use Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug Therapy, Combination - economics Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Insulin, Isophane - economics Insulin, Isophane - therapeutic use Male Metformin - economics Metformin - therapeutic use Middle Aged Models, Economic Poland - epidemiology Quality-Adjusted Life Years Sulfonylurea Compounds - economics Sulfonylurea Compounds - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!